bioXXmed AG

Informe acción XTRA:T5O

Capitalización de mercado: €2.4m

bioXXmed Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Mark-André Freyberg

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO24.3yrs
Participación del CEOn/a
Permanencia media de la direcciónsin datos
Promedio de permanencia en la Junta Directivasin datos

Actualizaciones recientes de la dirección

No hay actualizaciones

Recent updates

Is CytoTools (ETR:T5O) In A Good Position To Invest In Growth?

Jul 29
Is CytoTools (ETR:T5O) In A Good Position To Invest In Growth?

CytoTools AG (ETR:T5O): Are Analysts Optimistic?

May 12
CytoTools AG (ETR:T5O): Are Analysts Optimistic?

Loss-Making CytoTools AG (ETR:T5O) Expected To Breakeven In The Medium-Term

Jan 08
Loss-Making CytoTools AG (ETR:T5O) Expected To Breakeven In The Medium-Term

CEO

Mark-André Freyberg

24.3yrs

Permanencia

Dr. Mark-Andr? Freyberg co-founded bioXXmed AG (formerly known as CytoTools AG) in 2000 and serves as Chief Executive Officer since 2000 and had been the Chairman of Management Board until September 30, 20...